Geographic Atrophy

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

Presenters highlight clinical insights and lessons from recent trial data and surgical experience

ARCHER data reveal which GA eyes risk major vision loss: midrange baseline acuity and subfoveal lesions, shaping counseling and future AMD trials.

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, including in patients with concurrent neovascular AMD, per Nimesh Patel, MD, at ASRS 2026.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about a photovoltaic subretinal implant showing meaningful visual gains in patients with geographic atrophy due to AMD.

From a phase 3 durability readout for a first-in-class TKI to a new interchangeable ranibizumab biosimilar and a deep dive into geographic atrophy management, June brought a wide-ranging mix of regulatory, clinical, and practice-pattern news for retina specialists

Border zone lifetime gradient correlated with growth rate over 5 years

Not every question in the management of patients with GA has a clear answer—the two retina specialists work through the ones clinicians face most often in practice.

A prospective pilot study finds focal photopic microperimetry may detect cone-mediated losses that lesion size and visual acuity do not reflect.

A retrospective study identifies thin choroid as the key factor behind ungradable ultrawidefield green-light fundus autofluorescence images in geographic atrophy.

Dimitra Skondra, MD, PhD, FASRS, shares her perspective on the evolving treatment landscape for dry age-related macular degeneration and the key questions facing the field.

Findings from an 856-patient analysis suggest that evaluating GA topography beyond foveal involvement may better capture patient-reported functional impairment.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.

The Opti-GAIN study from Complement Therapeutics is assessing the safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD) of CTx001.

Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

The trial, sponsored by ONL Therapeutics, aims to enroll approximately 324 patients across sites in Europe, the United States, and Canada.

The successful completion and the milestone payment “provide Galimedix with an important operational runway to proceed with plans for additional clinical development in Alzheimer’s disease and other indications."

US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.

Leng discusses preliminary results from an ongoing study investigating the interaction between pegcetacoplan and anti-VEGF treatments in patients with GA.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA.

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.